A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine

Ronco, Claudio; Ronco, Federico; McCullough, Peter A.

doi:10.1007/978-3-030-45414-2_27

Cited by 4 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The department includes several divisions such as Cardiology, Cardiac Surgery, Vascular Surgery, Cardiac and Physical Rehabilitation, Pneumology, and Nephrology. The numerous publications by Prof. Ronco in cardiorenal medicine, dedicated books, and the present journal represent a demonstration that these disciplines, born isolated and focalized, are today merging in a new perspective of open science [7,8]. We sincerely hope that more cardiorenal departments will follow the one in Vicenza and will pave the way for important achievements and answers to currently unmet clinical needs.…”

mentioning

confidence: 80%

Editorial

McCullough¹

2021

Cardiorenal Med

View full text Add to dashboard Cite

mentioning

confidence: 80%

Editorial

McCullough¹

2021

Cardiorenal Med

View full text Add to dashboard Cite

“…Numerous recent papers have called for specific training in cardiorenal medicine and closer collaboration between nephrologists and cardiologists (40 –43). A larger community of nephrologists and cardiologists must be created, leveraging existing professional organizations.…”

Section: Clinical Trial Culture In Nephrologymentioning

confidence: 99%

Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease

Ishida

Chauhan

Gillespie

et al. 2021

CJASN

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease is a prevalent and prognostically important comorbidity among patients with kidney disease, and individuals with kidney disease make up a sizeable proportion (30%–60%) of patients with cardiovascular disease. However, several systematic reviews of cardiovascular trials have observed that patients with kidney disease, particularly those with advanced kidney disease, are often excluded from trial participation. Thus, currently available trial data for cardiovascular interventions in patients with kidney disease may be insufficient to make recommendations on the optimal approach for many therapies. The Kidney Health Initiative, a public-private partnership between the American Society of Nephrology and the US Food and Drug Administration, convened a multidisciplinary, international work group and hosted a stakeholder workshop intended to understand and develop strategies for overcoming the challenges with involving patients with kidney disease in cardiovascular clinical trials, with a particular focus on those with advanced disease. These efforts considered perspectives from stakeholders, including academia, industry, contract research organizations, regulatory agencies, patients, and care partners. This article outlines the key challenges and potential solutions discussed during the workshop centered on the following areas for improvement: building the business case, re-examining study design and implementation, and changing the clinical trial culture in nephrology. Regulatory and financial incentives could serve to mitigate financial concerns with involving patients with kidney disease in cardiovascular trials. Concerns that their inclusion could affect efficacy or safety results could be addressed through thoughtful approaches to study design and risk mitigation strategies. Finally, there is a need for closer collaboration between nephrologists and cardiologists and systemic change within the nephrology community such that participation of patients with kidney disease in clinical trials is prioritized. Ultimately, greater participation of patients with kidney disease in cardiovascular trials will help build the evidence base to guide optimal management of cardiovascular disease for this population.

show abstract

“…Few months ago a new paper by Claudio Ronco [70] pointed out as cardiorenal medicine should became part of physician's knowledge, especially for all people working in internal medicine's units.…”

Section: And Now?mentioning

confidence: 99%

Cardionephrology and cardiorenal disease in Italy: state of the art

Lullo

Bellasi

Barbera

et al. 2021

Reviews in Cardiovascular Medicine

Self Cite

View full text Add to dashboard Cite

The interactions and feedback mechanisms involved in heart and renal failure are more complex than previously thought and are grouped under the term "cardio-renal axis". In the last decades, it has always been emphasized that renal dysfunction in patients with heart failure can be attributed exclusively to low renal plasma flow resulting from reduced cardiac output. In the last two decades cardiorenal syndrome has been established to set complex and close interactions between heart and kidney. Cardiologists and nephrologist should interact in their daily clinical practice to provide better patients' management. In this review, we will point out main features of cardiorenal axis and cardiorenal syndrome to shift into specific sets of management in Italy starting by Guyton's hypothesis till present days.

show abstract

A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine

Cited by 4 publications

References 59 publications

Editorial

Editorial

Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease

Cardionephrology and cardiorenal disease in Italy: state of the art

Contact Info

Product

Resources

About